The price hikes come even as the Trump administration pressures pharmaceutical companies to lower costs for patients and ...

American pharma giant Pfizer ($PFE) leads the pack as pharmaceutical companies plan price increases for at least 350 branded ...

GSK (GSK) and other leading drugmakers plans to raise prices of as many as 350 medicines next year, with a median hike of ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.

Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in ...

Pfizer (NYSE:PFE) and GlaxoSmithKline (NYSE:GSK) are among the top drugmakers planning price increases for hundreds of ...

Even as the Trump administration wants drugmakers to cut prices, the median industry raise will be about 4%, similar to last ...

On December 16, Pfizer Inc. (NYSE:PFE) said the next few years are expected to be bumpy, starting in 2026. The company ...

Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

Pfizer has at least two key candidates in the pipeline that look like future winners. Merck has launched several products in ...